| Date Filed | Type | Description |
| 05/10/2023 |
SC 13D/A
| DUGGAN ROBERT W reports a 68.7% stake in Pulse Biosciences, Inc. |
| 12/09/2022 |
SC 13D/A
| DUGGAN ROBERT W reports a 81.8% stake in Summit Therapeutics Inc. |
| 08/18/2022 |
SC 13D/A
| DUGGAN ROBERT W reports a 81.2% stake in Summit Therapeutics Inc. |
| 06/10/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/02/2021 |
SC 13D/A
| DUGGAN ROBERT W reports a 51.2% stake in Pulse Biosciences, Inc. |
| 05/14/2021 |
SC 13D/A
| DUGGAN ROBERT W reports a 70.8% stake in Summit Therapeutics Inc. |
| 05/11/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/22/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/26/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 11/10/2020 |
SC 13D/A
| DUGGAN ROBERT W reports a 69.9% stake in Summit Therapeutics Inc. |
| 10/06/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 09/28/2020 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 06/17/2020 |
SC 13D/A
| DUGGAN ROBERT W reports a 47.2% stake in Pulse Biosciences, Inc. |
| 01/16/2020 |
SC 13D/A
| DUGGAN ROBERT W reports a 64.9% stake in Summit Therapeutics PLC |
| 12/27/2019 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 12/10/2019 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/12/2019 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/05/2019 |
SC 13D/A
| DUGGAN ROBERT W reports a 5.3% stake in Achaogen, Inc. |
| 03/28/2019 |
SC 13D/A
| DUGGAN ROBERT W reports a 6.8% stake in Achaogen, Inc. |
| 03/20/2019 |
SC 13D/A
| DUGGAN ROBERT W reports a 9.1% stake in Achaogen, Inc. |
| 03/13/2019 |
SC 13D/A
| DUGGAN ROBERT W reports a 11.1% stake in Achaogen, Inc. |
| 02/26/2019 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/22/2019 |
SC 13D
| DUGGAN ROBERT W reports a 48.8% stake in Summit Therapeutics, PLC |
| 01/18/2019 |
SC 13D/A
| DUGGAN ROBERT W reports a 5% stake in Aurinia Pharmaceuticals Inc. |
| 12/17/2018 |
SC 13D/A
| DUGGAN ROBERT W reports a 44% stake in Pulse Biosciences, Inc. |
| 12/12/2018 |
SC 13D/A
| DUGGAN ROBERT W reports a 20.4% stake in Achaogen, Inc. |
| 05/07/2018 |
SC 13D/A
| DUGGAN ROBERT W reports a 18.4% stake in Achaogen, Inc. |
| 04/23/2018 |
SC 13D/A
| DUGGAN ROBERT W reports a 15.7% stake in Achaogen, Inc. |
| 12/08/2017 |
SC 13D/A
| DUGGAN ROBERT W reports a 13.2% stake in Achaogen, Inc. |
| 10/23/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/19/2017 |
SC 13D/A
| DUGGAN ROBERT W reports a 7.3% stake in Achaogen, Inc. |
| 09/26/2017 |
SC 13D/A
| DUGGAN ROBERT W reports a 35.7% stake in Pulse Biosciences, Inc. |
| 09/18/2017 |
SC 13D/A
| DUGGAN ROBERT W reports a 26.7% stake in Pulse Biosciences, Inc. |
| 08/03/2017 |
SC 13D/A
| DUGGAN ROBERT W reports a 23.9% stake in Pulse Biosciences, Inc. |
|